[
    [
        {
            "time": "2021-08-16",
            "original_text": "东吴证券维持安图生物买入评级：2021年中报业绩基本符合我们预期，看好公司化学发光成长与平台化业务拓展",
            "features": {
                "keywords": [
                    "安图生物",
                    "化学发光",
                    "平台化",
                    "业绩"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "东吴证券维持安图生物买入评级：2021年中报业绩基本符合我们预期，看好公司化学发光成长与平台化业务拓展",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-08-17",
            "original_text": "太平洋维持安图生物买入评级：新冠影响逐步减小，IVD平台化具备优势",
            "features": {
                "keywords": [
                    "安图生物",
                    "新冠",
                    "IVD",
                    "平台化"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "太平洋维持安图生物买入评级：新冠影响逐步减小，IVD平台化具备优势",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-08-18",
            "original_text": "简评爱博医疗、安图生物、公牛集团",
            "features": {
                "keywords": [
                    "安图生物",
                    "爱博医疗",
                    "公牛集团"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "消费电子"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "简评爱博医疗、安图生物、公牛集团",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-08-19",
            "original_text": "安图生物(603658)：业务迅速恢复 多款新品推出成长动力十足",
            "features": {
                "keywords": [
                    "安图生物",
                    "新品",
                    "业务恢复",
                    "成长动力"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "安图生物(603658)：业务迅速恢复 多款新品推出成长动力十足",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-20",
            "original_text": "茅台创新低，一批牛股砸出深坑！大消费板块怎么了",
            "features": {
                "keywords": [
                    "茅台",
                    "大消费",
                    "牛股"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "消费品"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "茅台创新低，一批牛股砸出深坑！大消费板块怎么了",
                "Correlation": 2,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 1,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-21",
            "original_text": "安图生物(603658)半年报点评：Q2业绩进一步恢复 业务线向分子诊断拓展",
            "features": {
                "keywords": [
                    "安图生物",
                    "Q2",
                    "分子诊断",
                    "业绩恢复"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "安图生物(603658)半年报点评：Q2业绩进一步恢复 业务线向分子诊断拓展",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-22",
            "original_text": "安图生物上半年净利润增长51% 上海研发中心正式运营",
            "features": {
                "keywords": [
                    "安图生物",
                    "净利润",
                    "上海研发中心"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "安图生物上半年净利润增长51% 上海研发中心正式运营",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-23",
            "original_text": "A股异动 | 安图生物(603658.SH)涨6% 上半年净利同比增50.63%",
            "features": {
                "keywords": [
                    "安图生物",
                    "A股",
                    "净利增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "A股异动 | 安图生物(603658.SH)涨6% 上半年净利同比增50.63%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-08-24",
            "original_text": "半年报解读|安图生物H1业绩增长五成 董秘：基本达到公司预期目标",
            "features": {
                "keywords": [
                    "安图生物",
                    "半年报",
                    "业绩增长",
                    "董秘"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "半年报解读|安图生物H1业绩增长五成 董秘：基本达到公司预期目标",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-25",
            "original_text": "安图生物(603658)：业绩符合预期 化学发光试剂恢复高增长趋势",
            "features": {
                "keywords": [
                    "安图生物",
                    "化学发光",
                    "高增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "安图生物(603658)：业绩符合预期 化学发光试剂恢复高增长趋势",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]